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Abstract
Neuroblastoma originates from the cells in the neural crest. High-risk neuroblastoma, patients have poor outcomes even with the
multi-step treatment plans, including immunotherapy maintenance treatment. Researchers in developmental biology search for
unique antigens in neuroblastoma cells to utilize monoclonal antibodies (mAbs). Currently, GD2 is the most effective antigen that
scientists have isolated in the tumor; these anti-GD2 mAbs are administered in the forms of Dinutuximab or Dinutuximab beta to
attack the tumor. Monoclonal antibodies are currently administered in neuroblastoma instead of CAR T (that has seen success in
curing different types of leukemias) due to the heterogeneity of this tumor. Although GD2 treatment has made significant strides
in outcomes, there is still a high rate of relapse and treatment failure. Scientists continue to pursue further developments to help
cure high risk neuroblastoma through better technology and more research.
Introduction: Neuroblastoma accounts for 15% of all pediatric oncologic deaths and is the most common extracranial solid tumor
in children (Kholodenko et. al., 2018). Through understanding the tumor’s origin and developmental biology, researchers have
zeroed in on unique markers to utilize natural killers (NK) in targeting and eliminating the cancer. In the high-risk phase, neuroblastoma is deadly and has a high rate of relapse. Despite improvements in outcome, rates of recurrent neuroblastoma are high;
in about 50% of cases treatments fail (Jabbari,2019). Currently, the final part of the treatment plan is a monoclonal antibody
immunotherapy that targets the GD2 antigens on the cancer cells.
Origin
It is important to understand the developmental biology and neuroblastoma origins because its proliferation,
guide tissue morphogenesis, and differentiation resemble
cancer cells’ progression. From studying the unique physiology seen in the neural differentiation of the sympathoadrenal lineage, researchers can apply that knowledge to
treat neuroblastoma. For example, one of the backbones
of maintenance therapy is isotretinoin because scientists
found that the neural differentiation is driven by retinoids
in vitro (Cheung and Dyer,2013).
The neural crest cells that form neurons can be divided into five functional types: vagal, sacral, cranial, cardiac
and trunk cells. The trunk cells then separate into two
lineages in the early stages of embryonic development
– sympathetic and adrenal. When the cells migrate from
the neural crest, they undergo epithelial-mesenchymal
transition (EMT). Both neural crest cells and tumor
cells undergo similar EMT processes and express matrix
metalloproteinases (MMPs), disintegrins and metalloproteinases (ADAMs) that facilitate cell invasion and migration (Kholendenko, 2018).
The migrating neural crest progenitor cells committed
to the sympathoadrenal lineage initiate their differentiation due to the signaling of bone morphogenetic protein
(BMP). The cells then commit to becoming either adrenal
chromaffin cells or sympathetic ganglia. Members of the
MYCN family are expressed throughout this process in
the migrating trunk neural crest cells and are committed
to the sympathoadrenal lineage (Cheung,2013).
Neuroblastoma arises from the progenitor cells of
sympathoadrenal lineage of the neural crest during development. More specifically, scientists believe that neuroblastoma may develop from this chromaffin lineage
because most tumors are localized in the adrenal gland
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region.The expression of different transcription factors is
critical for neural crest development and is upregulated
in cancers including Snail, Twist, SoxE, and FoxD families.
The neural crest cells are a transitional type of cell that
quickly pass from multipotent progenitors to a variety
of differentiated cell types. Scientists previously thought
that the neural crest cells gradually lose their multipotent
properties and plasticity when they reach the postmigration stage, but it has been seen that is not the case.
Adult neural crest-derived cells retain the properties of
stem cells and even mimic the transcriptional expression
profiles of both embryonic stem cells and neural crest
progenitors. These progenitor cells of the neural crest
are found in many types of tissues, including skin, dorsal
root ganglia, adrenal medulla, bone marrow, among other
tissues (Kholendenko et. al., 2018).
Presentation of Neuroblastoma
A 2016 study showed that 50% of neuroblastoma patients presented with metastases at diagnosis (Tolbert
and Matthay 2018). Most cases of neuroblastoma are
diagnosed in the abdomen or arise in the adrenal medulla
or lumbar sympathetic ganglia. (Cheung, 2013).The tumor
can appear anywhere from the neck to the pelvis because
the origin is along the paraspinal and sympathetic ganglia.
The clinical presentation varies based on the tumor’s primary and secondary metastatic sites (Tolbert and Matthay,
2018).The most common metastatic site is the bone marrow, at 89%; therefore, bone marrow aspirates are used
for diagnosing and responding to the cancer (ShumacherKuckelkorn, 2020). Due to the tumor’s involvement
with the central nervous system (CNS) other common
metastatic sites are bones and regional lymph nodes.
Tumors can present at the top of the paraspinal ganglia,
causing Horner’s syndrome in some patients because
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neuroblastoma involves surrounding nerve roots of the
sympathetic ganglia. Thoracic tumors present in only
5% of patients, arising from the posterior mediastinum
and paraspinal ganglia, and, often, the tumor will invade
the neural foramina. The neural foramina can be invaded
anywhere adjacent to the spinal cord compressing it. In
the abdominal cavity, masses can cause distention with or
without pain. Furthermore, extensive liver involvement
can be seen in infants and can cause liver disease such
as coagulopathy as well as renal and lung dysfunction
due to abdominal distention. The neurologic symptoms
that can accompany pelvic tumors include bladder dysfunction, constipation, lower extremity pain or weakness
due to nerve root involvement. Another symptom seen
predominantly in infants’ metastases in the skin is painless subcutaneous nodules that have a blue hue. If the
tumor metastasizes in the bone of lower extremities, the
patient may limp or refuse to bear weight. Only 80% of
patients who need bone marrow infiltration will present
with anemia and thrombocytopenia. The common symptom of racoon eyes is caused by bone lesions in the skull,
within the periorbital region, that can cause periorbital
bruising. The catecholamines released can cause flushing,
hypertension, or tachycardia, and in rare cases, a paraneoplastic phenomenon will secrete vasoactive intestinal
peptides causing profuse diarrhea. If children present with
opsoclonus myoclonus syndrome (OMS) or varying neurologic symptoms such as opsoclonus, myoclonus, ataxia,
or other cerebellar symptoms, they should be tested for
neuroblastoma. Fifty to eighty percent of these patients
will then be diagnosed with neuroblastoma, but only
2-3% of neuroblastoma patients are affected by OMS.
(OMS can be attributed to the anti-neuronal antibodies
cross-reacting with the cerebellum.) (Tolbert,2018)
Stages of Neuroblastoma
The international neuroblastoma community organized
neuroblastoma into four distinct stages.The first L1, is a localized tumor confined to one body compartment, which
does not involve vital structures as defined by the list of
image-defined risk factors.The second stage L2, is a locoregional tumor with presence of one or more image-defined
risk factors. The third stage is M: a distant metastatic disease. MS is confined to children younger than 18 months metastases are confined to skin, liver and/or bone marrow.
Further classification is based on age, histologic category,
grade of tumor differentiation, MYCN amplification, 11q
aberration and ploidy (Tolbert,2018). Patients with low-risk
classifications have a favorable prognosis with >90% survival; in contrast, patients with high-risk neuroblastoma have a
5-year survival rate that is still below 50% (Weinke,2021).

Treatment Steps Overview
Most children who present with low and intermediate
risk disease respond well to treatment plans, but children
with high-risk neuroblastoma need an intense “multimodal” approach as the cure rates are estimated at <50%
(Khan et. al., 2021). The current treatment for high-risk
neuroblastoma has three phases and lasts approximately
18 months. Induction, the first phase, is where patients receive 5–8 cycles of intensive chemotherapy and start stem
cell collection to prepare for their autologous stem cell
transplant (ASCT). Surgery is usually preformed towards
the end of this phase (Smith and Foster, 2018). Next is
consolidation, which includes high dose chemotherapy
followed by ASCT, shown to be especially beneficial in neuroblastoma, unlike in most other high-risk diseases with
solid tumors (Khan, 2021). Radiation therapy usually starts
after ASCT recovery. The last step is maintenance, which
deals with the residual disease, trying to prevent the 50%
relapse rate (Smith,2018). This phase uses immunotherapy
which is a combination of monoclonal antibody targeting
called disialoganglioside (GD2) / Chimeric antibody 14.18
(ch14.18), GM-CSF, and interleukin-2 (IL-2), which were
added to previous maintenance therapy of just administering isotretinoin. In the cases when the patient relapses or
the cancer becomes refractory, the cancer is rarely cured.
Salvage therapy is administered to improve symptoms and
quality of life (Tolbert and Mathey, 2018).
Monoclonal Antibodies’ History
B-lymphocytes are activated when a foreign substance enters the body, and antibodies are produced in response to
this antigen. Monoclonal antibodies (mAbs) are the main
antibodies used in immunotherapy treatment for cancer.
The history of mAbs began in 1975 with future Nobel
Prize winners Georges Kohler and Cesar Milstein using
hybridoma technology to produce mAbs, an antibody
that only recognizes a single epitope. Antibodies that are
made for immunotherapy are based on the Fv’s region
affinity for antibody targeting and the Fc’s region ability
to participate in the host’s immune system.The two classes of mAbs are non-conjugated: naked mAbs and mAbs
that work with chemo drugs or radioactive particles that
target to enable the mAbs to reach the objective. MAbs
use three different mechanisms of action via targeting and
binding the target cell’s antigen on the cell membrane and
blocking the pathways that lead to the cells multiplying.
Firstly, they inhibit the factors and receptors that activate
the pathways allowing cancer cell proliferation. Second,
they cause antibody dependent cell-mediated cytotoxicity (ADCC), where the mAbs bind to the tumor associated antigens in the surface of target cells. Then the
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Fc receptors of immune cells recognize cell-bound mAbs,
followed by cross-linking of these receptors, releasing cytotoxic agents that lead to apoptosis of tumor cells. The
third way is through complement dependent cytotoxicity
(CDC). The mAbs bind to the antigen on the target cell,
causing a “complement cascade”. These complements
bind an attack complex and activate the cell’s complement system lyses (Kimis-Gebologlu et. al., 2018).
GD2
Scientists isolated GD2 for the mAbs to target. GD2 in
its humanized forms is called hu3F8 and ch14.18. GD2 is
an oncofetal differentiation antigen that was identified
by comparing neuronal differentiation and tumorigenesis
(Cheung,2013). GD2 is a perfect candidate for antibody
therapy because it is abundantly expressed in most neuroblastoma cells, and GD2 is limited in normal cells, including peripheral nerves (Nguyen et. al., 2018). It belongs to
a unique class of T cell-independent carbohydrate antigens
with high density, membrane proximity, homogeneity within
and across neuroblastomas, and rare occurrence of antigen
loss. Anti-GD2 mAbs attach tumor cells to NK cells and
rescue NK cells from being suppressed or inhibited by neuroblastoma. GD2 is also ideal for tumor-selective delivery of
radioisotopes, liposomes, or nanoparticles (Cheung,2013).
Further future applications of GD2 were seen in association with tumor-associated macrophages (TAMs). These
TAMS are myeloid effectors that can become polarized
into type 1 antitumor or type 2 pro-tumor phenotypes.
But researchers discovered that in the presence of anti-GD2 mAbs in vitro, ADCC can turn protumor M-CSFactivated macrophages into antitumor killers. Even though
mAb therapy is considered a passive immunotherapy, introducing a host anti-tumor following mAb therapy might
benefit long-term tumor control (Cheung,2013).
MYCN, KIR-HLA, ALK, ATRX
In addition to GD2 researchers continue to search for
unique features of the tumor that can lead to a cure.
Scientists specifically look at the distinctive genes and
mutations seen in a lot of cases and the effect they have
on the outcomes.
Only less than two percent of patients have mutations
in the signaling pathways involved with the sympathoadrenal line that causes familial neuroblastoma. PHOX2B
was another mutation identified that promotes cell cycle
exit and neural differentiation. Though in sporadic neuroblastomas, 6-10% carry somatic anaplastic lymphoma
receptor tyrosine kinase (ALK) activating mutations,
while 3-4% have a high frequency of ALK gene amplification. ALK plays a role in ensuring the balance between
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proliferation and differentiation. (PHOX2B and ALK gene
have been linked because PHOX2B may directly regulate
ALK expression) (Cheung,2013). ALK is expressed only
in neural tissues, and mAbs designed to recognize ALK on
neuroblastoma cell surfaces have shown increased ADCC
of ALK-amplified NB cells. This ALK expression is linked
to the MYCN expression (Jabbari,2019).
The most common focal genetic lesion in sporadic
neuroblastoma is MYCN amplification. It is a major oncogenic driver since it controls proliferation, growth, differentiation, and survival of cells in the developing CNS
(Cheung,2013). MYCN is expressed prenatally in different
tissues, but its expression is lost during the first week postnatally. MYCN amplification is associated with metastases,
reduced T-cell infiltration to TME, and invasiveness of the
tumor and its progression during induction treatment. But
MYCN-amplified patients were found to have better early
response to treatment, however their survival rates were
unaffected. Recent studies have employed miRNAs to suppress MYC family (Jabbari,2019).
ATRX mutation is another mutation seen in some neuroblastomas. ATRX is associated with increased telomere
activity that is vital for the cancer cells to survive.This high
telomere activity is found in 30% of neuroblastomas at
diagnosis and is predictive of reduced EFS and overall survival. There are currently no molecular therapies targeting
these pathways associated with telomeres (Cheung,2013).
NK cells are capable of inhibiting colony formation of
human neuroblastoma cells and infusion of NK cells into
mice bearing human metastatic neuroblastoma showing
improvement in OS (Venstrom,2009). NK activity is regulated by inhibitory and activating signals following engagement of cell membrane receptors with their cognate
ligands on target cells (Tarek,2012).
NK cells expressing inhibitory killer cell immunoglobulin-like receptors (KIR ligand) for self- human leukocyte
antigen (HLA) class I molecules are equipped with effector function, ensuring that potentially autoreactive NK
cells expressing KIR for non-self HLA (“missing ligand”)
are not able to work when they encounter cells lacking
their cognate ligand. (Venstrom,2009). Untreated NB tumors and cell lines are widely reported to have reduced
to no HLA class I expression, rendering them potentially
susceptible to NK killings due to lack of engagement of
HLA class I–specific inhibitory KIRs (Tarek,2012).
Clinically, the “missing ligand” KIR-HLA compound genotype is a strong predictor of response and survival.When
treated with anti-GD2, patients with neuroblastoma who
lack one or more HLA ligand for their inhibitory KIRs
respond better to treatment, have lower rates of relapse,
and survive longer compared with patients who possess
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all HLA KIR ligand. This suggests that the unlicensed NK
cells expressing KIRs for non–self-HLA ligands are more
effective in tumor eradication than the licensed NK cells
expressing KIRs for self HLA. HLA class I expression on
neuroblastoma cell lines selectively inhibits licensed cell
activity, allowing unlicensed NK cells to mediate ADCC,
showing the importance of unlicensed NK cells for the
antitumor role in patients undergoing mAb therapy. This
explains the “missing KIR ligand” benefit in patients with
neuroblastoma. Since licensed NK cells expressing S-KIRs
have higher ADCC capacity in general, rescuing licensed
NK activity from class I inhibition is advantageous because it could increase response in all patients, even those
with all the KIR ligands present (Tarek,2012).
In addition, the use of exogenous NK cells in the treatment of patients with NB may be potentially useful if
the patient lacks class I ligands for the donor inhibitory
KIRs. Augmentation of innate immunity through adoptive
transfer of allogeneic NK cells or the use of agents that
increase endogenous NK cell number and activity, such
as IL-2, lenalidomide, and anti-CD137 antibody, may all
improve NB control, particularly in the presence of 3F8.
While transplantation and mAb therapy are hardly normal physiological conditions, they both take advantage
of the important pool of unlicensed NK cells, previously
thought to be hyporesponsive and therefore potentially
less clinically relevant. (Tarek,2012).
GM-CSF, IL 2, Retinoid Acid
Dinutuximab is augmented by GM-CSF and IL-2 because
they stimulate the immune response and specifically the
antitumor effect. IL-2 works to stimulate NK cells, and
GM-CSF activates granulocyte and macrophage cytotoxicity (Armideo et. al.,2017). Granulocyte-macrophage
colony-stimulating factor (GM-CSF) is a cytokine that
enhances the activity of macrophages (Jabbari,2019).
IL-2 is an important component of immunotherapy because it can improve the cytolytic function of NK cells
against neuroblastoma cells. Though 23% of patients receiving IL-2 suffer from capillary leaks, IL-15 has been
considered as an alternative to IL-2 for combination
with anti-GD2 mAbs in neuroblastoma. Furthermore,
administration of IL-15 is necessary for the NKT cells, an
anti-neuroblastoma lymphocyte, to survive the hypoxic
neuroblastoma environment (Cheung and Dyer, 2013).
The International Society of Pediatric Oncology Europe
Neuroblastoma (SIOPEN) has even removed IL-2 infusions with dinutuximab beta because of the toxicities
related. They suggest dinutuximab beta and isotretinoin
for maintenance therapy (Ladenstein et. al., 2020). The
isotretinoin is used with anti-GD2 as a differentiating

agent that induces the maturation of neuroblastoma
cells since GD2 is a marker on only mature neurons
(Armideo et. al., 2017).
Reasons CAR T does not Work in
High-Risk Neuroblastoma:
Neuroblastoma is an extremely heterogeneous disease,
meaning each tumor has unique molecular, cellular, and
genetic features, all affecting the tumor’s response to the
treatment. It can continue to metastasize or even become
refractory to a specific therapy. Furthermore, scientists
are unsure how heterogeneity evolves with treatment and
disease progression remains unknown. Neuroblastoma
has a narrow epitope range hence the T cell-based therapy is not effective; therefore, antibody-based immunotherapy is used targeting GD2, and oncofetal antigens.
Unlike its restriction in normal tissue, GD2 (disialogangliosides) present on tumors that arise from the neuroectoderm (neuroblastoma, melanoma, small cell lung cancer,
and sarcomas) are expressed.. Also, there are few natural
antibodies opposed to neuroblastoma. Further, fighting
the rare variants of somatic mutations seen in neuroblastoma contrast with the lack of mutations in adult cancers.
Then the intensive use of chemotherapy further damages those T cells that were attacking the neuroblastoma.
Specifically, active adaptive immunity is harder for patients
with high-risk neuroblastoma because of the primary and
metastatic tumor’s bulk together with its rapid proliferation that overwhelms the immature immune system in
children (Cheung,2013). Another technique used to gain
long term control over cancers is an immune checkpoint
blockade that targets the immune system by activating
previously exhausted or dysfunctional T cells.These mAbs
(programmed cell death protein 1 (PD-1) and cytotoxic
T-lymphocyte-associated protein 4 (CTLA-4)) used in the
blockade in adults’ tumors are efficient, but in pediatric
tumors, these checkpoint inhibitors have shown no significant benefit (Liu,2020).
Neuroblastoma recruits pro-tumor macrophages and
silences natural killer (NK) cells. Furthermore, neuroblastoma evades T cells by downregulating or losing human
leukocyte antigen (HLA) expression, but they simultaneously cause damage by re-expressing HLA to resist NK
cell-mediated antibody dependent cell-mediated cytotoxicity (NK-ADCC). Once bound to GD2, anti-GD2 mAbs
bind to Fc-receptors on the surface of granulocytes and
neurokinin cells and eliminate NB cells through ADCC
and CMC (Jabbari et. al., 2019).
Side Effects of Anti-GD2
As with all treatments when dinutuximab - using mouse
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SP2/0 cells (and dinutuximab beta- In Europe) was recloned in Chinese hamster ovarian (CHO) cells), is administered, patients can experience a range of adverse
effects (McKeage et. al., 2018; Ladenstein, 2020).
Dinutuximab beta was also found to be a cost-effective
treatment option (Pennington,2019). Dinutuximab beta is
an orphan medicine that is approved in the EU for the
treatment of high-risk neuroblastoma in patients aged 12
months who have previously received induction chemotherapy, and achieved at least a partial response, followed
by myeloablative therapy and SCT, relapsed or refractory neuroblastoma ± residual disease (Ladenstein, 2020).
The continuous, 10-day infusion regimen appears to be
associated with less toxicity than the once-daily infusion
on 5 consecutive days (McKeage,2018). These side effects
usually do not continue once treatment ends, but it may
interrupt the treatment.
Doctors can prescribe medications during treatment to
deal with some of the side effects. The most frequent of
these is neuropathic pain. This appears to be caused by
dinutuximab, which targets GD2, a protein that is present
on the neuroblastoma cell and is also present on neurons and peripheral nerve fibers, which causes the pain
(Bartholomew, 2017). The pain can be controlled to some
extent by analgesic therapy, including intravenous morphine, prior to and during the infusion (McKeage et. al.,
2018). Furthermore, infusing an antibody can cause severe
reactions including anaphylaxis and cytokine-release syndrome (Bartholomew et. al., 2016). Since 39% of patients
run a fever, acetaminophen is administered prophylactically prior to treatment (Armideo et. al., 2017). The fever
may stem from a few different factors including, the IL-2
releasing pyrogenic factors, immune stimulation or the
cytokines that are released when the antibody is administered (Bartholomew,2017). Patients may also require
premedication of antihistamines before each infusion.
Furthermore, Dinutuximab can cause hypersensitivity
reactions (25%) and even more so when IL-2 and dinutuximab are administered together; this is due to immune
stimulation and cytokine release (Aust Prescr,2020).
The 23% of patients that experience capillary leak syndrome (CLS) can be attributed to endothelial cell damage,
a cytotoxic response of dinutuximab, GM-CSF, and IL-2.
Common treatment for CLS uses furosemide, which has a
higher association with hypokalemia (Bartholomew,2017).
The rare side effect of a liver dysfunction can be evidenced through the elevated alanine transaminase (ALT),
(23%); and aspartate transaminase (AST) (10%) along with
electrolyte disturbances (Armideo,2017). A small population have ocular changes such as mydriasis and accommodation issues along with anisocoria and sluggish pupillary
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response; therefore, patients should be monitored for
photophobia, papillary reactivity, and visual changes
(Bartholomew,2017). Other common toxicities seen are
infection (39%), hypokalemia (35%), hyponatremia (23%),
gastrointestinal side effects (nausea, vomiting, diarrhea;
22%), hypotension (18%), hypoxia (13%), and urticaria.
(Armideo,2017).
Immunosuppressive Environment:
Factors that are unique to pediatric solid tumors are the
paucity of neoantigens, development of resistance, and
an immunosuppressive environment. The neuroblastoma
tumor microenvironment (TME) studies have identified
tumor associated macrophages (TAMs) within the immunosuppressive microenvironment in neuroblastoma that
specifically inhibit both innate and adaptive immune responses (Liu,2020).
Other immunosuppressive components affecting the T
cells function in attacking the tumor are defects in antigen
presenting machinery (APM) and low levels of MHC class
I molecule displayed by neuroblastoma tumor cells that
lead to decreased cytotoxic T-cell activation. Secretion of
different solubles, including transforming growth factor-β
(TGF-β), and galectin-1 by tumor cells, directly inhibits
T cell function. Furthermore, some myeloid cells in the
tumor may not fully differentiate into dendritic cells, macrophages, or granulocytes, but instead generate a heterogeneous population of immature immunosuppressive myeloid cells, MDSCs. Hypoxia-inducible factor 1α (HIF1α)
is a soluble factor that promotes the differentiation of
MDSCs into TAMs, creating a feedback loop to support
immunosuppression. Targeting these MDSCs enhance anti-tumor immune responses in neuroblastoma, implying
that MDSCs play roles in cancer-related inflammation,
enhancing the tumor’s progression (Liu and Joshi, 2020).
Cytokines can be used for intercellular communication;
therefore, the cancer cells can use them to alter the TME
according to their needs. When tumor cells release VEGF,
which promotes angiogenesis within TME, it is usually associated with higher stages of neuroblastoma and its poor
prognosis. IL-6 is a cytokine, that positively affects tumor
growth and distant metastases while IL-10 is an immunosuppressive cytokine found in neuroblastoma. Blocking
IL-10 receptors has been shown to enhance immune response to tumors and improve outcomes of treatment.
Also, INF-γ, a cytokine, can also induce tumor regression
by promoting ADCC (Jabbari et. al, 2019).
Traditionally the thymus eliminates T-cells through T-cell
receptors (TCRs) with high affinity toward tumor (self)-antigens. T-cells with high-affinity TCRs can be eliminated or
converted into regulatory T-cells (Tregs) (Jabbari,2019).
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Treg cells exhibit their suppressive activity via several
mechanisms including inhibition of antigen-presenting
cell maturation through the CTLA-4 pathway, secretion
of inhibitory cytokines such as IL-10, TGFβ, IL-35, and
granzyme and perforin expression that kill effector T-cells.
Studies are currently inconclusive of Treg’s exact effect
on patients with neuroblastoma, but they do correlate a
higher proportion of Treg cells in the bone marrow and
peripheral blood with MYCN amplification (Liu,2020).
Since Tregs lack IL-7Rα, it can be exploited for increasing
expansion and enhancing function of CAR T-cells without
concomitant expansion of Tregs (Jabbari,2019).
Further challenges stem from the neuroblastoma cells.
Gangliosides and sialic are highly expressed surface carbohydrates that are important for migration, adhesion, and
metastasis, but are also poorly immunogenic and sometimes even immunosuppressive. Since natural anti-ganglioside antibodies are rare, it allows the neuroblastomas to
survive in the circulation despite not having a complement
decay accelerating factor (CD55). Myeloid suppressor
cells, regulatory T cells, and it exploits protectin (CD59)
to resist or suppress immunity (Cheung and Dyer, 2013).
Further Developments
Almost 80% of patients with the clinically aggressive disease do not show sustained responses to recent advances
in anticancer therapy. More research is necessary to understand neuroblastoma’s biology and an accurate representation of the tumor to identify agents that can be used
in pediatric drug development. Additionally, since there is
a low occurrence of neuroblastoma there are less clinical
trials (Corallo et. al., 2020).
Current neuroblastoma studies primarily employ
two-dimensional (2D) cell cultures. A three-dimensional (3D) culture would improve the research since it can
reconstruct a physiologically relevant TME. Also, current
models do not reflect the pediatric context of neuroblastoma, immature immune systems, differences in drug
metabolism, and continuing developmental changes. A 3-D
platform would also address the lack of clinical trials issue
and can lead to more efficient treatment plans, hopefully
reducing the exposure of pediatric patients to additional
rounds of chemotherapy (Corallo et. al., 2020).
Scientists have looked at instances of spontaneously
regressing neuroblastomas (NBL-4S) where an advanced
metastasizing neuroblastoma that had spread to the skin,
peripheral blood, bone marrow, and peripheral ganglia
(but excluding the bone) suddenly regresses.This situation
shows that neuroblastoma may be different and disconnected from the GD2 marker. Although GD2 is present
in NBL-4S, the study showed its expression may be lower

(this should infer a worst prognosis, but the exact opposite occurred). Scientists have not been able to define the
immune response nature and signature of neuroblastoma
rejection in NBL-4S, but they assume NK cells are involved
(Rovigatti,2021).
Researchers are working on a vaccine to prevent neuroblastoma relapses. Once integrated to the cell genome,
lifelong expression of transfecting genomes can detect
neuroblastoma cells presenting the tumor associated
antigens (TAAs). This is of utmost importance in cases
of minimal residual disease. Vaccines have been directed
against TAAs such as survivin, MYCN, and GD2 have been
somewhat effective for this purpose. Retroviruses have
been used to transfer IL-2 genes to neuroblastoma cells in
mice and have resulted in sustained production of IL-2 and
tumor growth control in these animal models, and neuroblastoma cells transfected with IL-1β and TNF-α by means
of retroviral vectors showed tumor growth arrest in vitro
(Jabbari,2019).
Neuroblastoma evades the attack of the mAbs by escaping to the CNS, which is not accessible to circulating antibodies (Cheung,2013). Studies are working to create an
anti GD2 CAR T treatment to redirect T cells against GD2
(Prapa,2015). Though CAR T treatment has a long way to
go until it will be effective; therefore, there is not sufficient
evidence to abandon the advantages of passive immunotherapy with anti-GD2 monoclonals (Ugo Rovigatti.2021).
Scientists used an anti-GD2 single-chain variable fragment
(scFv) derived from a murine antibody of IgM class that
was linked to the signaling domains of the costimulatory
molecules 4-1BB (CD137) and CD3-ζ. The receptor was
expressed in T lymphocytes. Then transduced T cells expressed high levels of anti-GD2 CAR into cultures that
infiltrated the tumors and persisted into blood circulation
inducing massive apoptosis of neuroblastoma cells and
destroying the tumor growth. Since the preclinical had
positive results, more clinical testing with this approach
will be tested in neuroblastoma and other GD2-positive
malignancies (Prapa et. al., 2015).
Conclusion
Cancer treatments have improved greatly throughout
the years, but researchers are still looking for the best
way to eliminate high risk neuroblastoma. The current
treatment plans employ the use of an immunotherapy
using mAbs that targets the GD2 antigens on the tumor
cells. Although this treatment has toxicities while it is administered, there is an overall higher EFS rate in patients
receiving it in their maintenance therapy. Sadly, the rate of
relapse is still high with the GD2 treatments; therefore,
researchers continue to search for better options.
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